Life Sciences Strategy Summit on IP & Exclusivity returns to Munich with IPKat readers’ discount

"Kitten" in Munich

As it has become somewhat of a tradition, the Katfriends at Kisaco Research wish to inform IPKat Readers that their Life Sciences Strategy Summit on IP & Exclusivity returns to Munich this October (13–15 October 2025, Infinity Hotel) and promises to be bigger, broader, and more commercially relevant than ever before.

Against a backdrop of shifting case law, evolving EU regulations, and the rise of the UPC, this year’s summit is a key place where originators, generics, biosimilars, biotech, regulators, and law firms come together to shape the future of IP strategy in Europe.

This year’s agenda features the following speakers:

In-House Counsel Highlights:

• James Horgan, Chief IP Counsel – Policy & Litigation, MSD
• Julia Pike, Global Head of IP, Sandoz
• Ana Gabarda, Director – Corporate Patent Counsel, Merck
• Toni Santamaria, SVP Intellectual Property & Legal, Adalvo
• Maurizio di Stasio, Senior Patent Counsel, Bayer
• Mathilde Rauline, Head of Greater Europe Patent Litigation, Sanofi
• Fleur Herrenschmidt, Chief Legal Officer, Norgine
• Natalia Wright, Associate General Patent Counsel, UCB
• Plus many more from Novartis, Amgen, BioNTech, Fresenius Kabi, Chiesi, Polpharma, Regeneron, and others

Judicial & Patent Office Faculty:

• Martin Schmidt, Technically Qualified Judge, UPC
• Roberto Romandini, Legal Member, Boards of Appeal, EPO
• Oliver Werner, Head of SPC Working Group, German PTO
• Patrick Purcell, Senior Patent Examiner, UK IPO
• Fergal Brady, Patent Examiner, Irish IPO
• Damien Filippini, Patent Engineer, INPI
• And more, providing direct insights into case law and procedural shifts

With over 50 senior in-house counsel, patent office examiners, and UPC judges, participants will gain a 360° view of the legal, regulatory, and competitive challenges driving exclusivity decisions across the life sciences sector.

New to the 2025 edition are the following topics:

• Unitary SPC developments: What a centralized SPC system means for exclusivity strategy.
• Patent quality across EPO & PTAB: Tackling unpredictability and enforcement challenges.
• AI in Life Sciences IP: Regulatory changes, FTO implications, and future-proofing strategy.
• Divisional patents in EU & US: Impact of Teva cases and FTC decisions.
• Bolar exemptions & safe harbor: Cross-jurisdictional differences shaping trial strategies.
• Second medical use & skinny labels: Navigating complex enforcement landscapes.
• Regulatory exclusivity reforms: New EU legislation, Tecfidera implications, and portfolio management.
• Antibody exclusivity: EPO vs USPTO comparisons, inventive step debates, and Amgen/Sanofi impact.

Also this year, IPKat readers are entitled to a 15% discount in the registration fee by using VIP code IPKATSM15 at checkout. For further information and to register, click here.